|
Hologic has received correspondence arising from litigation.The litigation alleges that a 48-year-old patient was implanted on (b)(6), 2022 with a biozorb marker following a surgical procedure for a left breast lumpectomy.On (b)(6) 2024 the patient presented with complaints of biozorb marker failing to dissolve and it bothered the patient.Patient requested to have the biozorb marker removed.It was removed on the same date with the mention that an infection was not present at the date of removal.No other relevant information was provided.This report is being submitted pursuant to 21 cfr part 803 based on information made available to hologic through litigation.Consistent with 21 cfr 803.16, the submission of this report is not intended, and shall not be construed, as an admission, acknowledgment, or confirmation by hologic that the device caused or contributed to the reportable event.
|